Can I Use Regular Mupirocin in My Nose? Safety, Timing, and Prescription Rules

Yes, you can use regular mupirocin ointment in your nose — but only when a clinician has prescribed it for that purpose, and only as a short, time-limited course. Mupirocin 2% ointment is the exact drug and strength that has been studied for nasal decolonization of Staphylococcus aureus, and regulated labeling elsewhere in the world describes nasal application twice daily for five days. The catch: many regular tubes, especially 22-gram tubes sold for skin infections, are labeled for topical skin use only, and self-treating the nose with them can select for resistance and irritate the nasal lining.

Why Mupirocin Works Inside the Nose

Mupirocin is a polyketide antibiotic produced by the bacterium Pseudomonas fluorescens. Its target is bacterial isoleucyl-tRNA synthetase, an enzyme that loads isoleucine onto its transfer RNA. When mupirocin binds that enzyme, protein synthesis stops and the bacterium dies or cannot divide. This is a narrow, specific mechanism, and that specificity is why mupirocin does not wipe out the whole nasal microbiome the way a broad-spectrum oral antibiotic would.

The nasal vestibule — the front 1 to 2 centimeters inside each nostril — is the primary reservoir for Staphylococcus aureus in roughly 20 to 30 percent of healthy adults. The anterior nares harbor far more staph than the skin or throat, and nasal carriage is the single strongest risk factor for subsequent staph infection at other body sites. Decolonizing that reservoir is the entire rationale for putting an ointment into the nose.

Mupirocin ointment is formulated in a polyethylene glycol base at 2% concentration, meaning 20 milligrams of drug per gram of ointment. That base is thick, water-miscible, and occlusive. In the nose it clings to the vestibular mucosa long enough to deliver drug to the bacteria sitting there, usually for several hours per application.

The Two Mupirocin Products Most People Confuse

This is where most of the confusion starts. There are two distinct prescription mupirocin products, and the word "regular" means different things depending on which one you are holding.

The nasal-specific cream (often called Bactroban Nasal in the UK) comes in tiny 3-gram tubes, one per nostril per course. The regular 22-gram ointment tube is labeled for impetigo and other skin infections. Both contain 2% mupirocin. The drug is the same; the base, tube size, and labeled indication differ.

In the United States, mupirocin 2% ointment carries an FDA-approved skin indication, and nasal use is off-label but widely accepted in clinical practice for MRSA decolonization, typically at 2% twice daily for 5 days. The nasal cream formulation is not marketed in the US. In the UK and much of Europe, a nasal-specific cream is licensed and labeled for nasal use — the regulated indication exists there.

What the Research Actually Shows for Nasal Use

The most-cited trial is the Mupirocin and the Risk of Staphylococcus aureus Study (MARS) from 2003, which randomized roughly 1,600 nasal carriers to mupirocin or placebo and found a 48 percent relative reduction in S. aureus infections over about a year. That is one of the strongest pieces of evidence for nasal decolonization as a strategy.

Surgical-site infection trials have produced mixed results. A large randomized trial by Perl and colleagues published in 2002 found that mupirocin nasal ointment plus chlorhexidine bathing reduced surgical-site infections in nasal carriers of S. aureus. But later studies showed the benefit concentrates almost entirely in people who are actually colonized — treating non-carriers with mupirocin adds cost and resistance pressure without reducing infections.

For MRSA decolonization in hospitals, current guidance from major infection-control bodies generally describes a bundle: nasal mupirocin twice daily for 5 days, usually combined with chlorhexidine bathing, for patients at high risk of invasive staph infection. Per the 2024 SHEA/IDSA/APIC compendium on strategies to prevent MRSA transmission, mupirocin-based nasal decolonization remains a core component of targeted and universal decolonization protocols.

The nasal formulation's original pivotal trial used twice-daily application for five days and reported elimination of nasal carriage in about 90 percent of treated patients at short-term follow-up. That figure is the basis for the "5-day course" that appears on almost every nasal mupirocin label.

A Step-by-Step Timeline of a Nasal Course

If a clinician prescribes regular mupirocin ointment for the nose, the sequence looks like this.

Each individual application typically takes under a minute. The most common timing mistake is treating the nose only once a day, which reduces efficacy and is not what any trial used.

Dosing, Amount, and How the Numbers Add Up

The standard nasal dose is a small but not tiny amount — often described as "about the size of a match head" or "half a fingertip" in each nostril. Squeezing a long ribbon of ointment up into the nose is wasteful and increases irritation.

One 22-gram tube of regular mupirocin ointment contains enough drug for roughly 10 to 15 standard 5-day bilateral courses, depending on how generous each application is. A nasal-specific 3-gram tube is sized for exactly one 10-application course, with a little spare margin. If your prescription is written for the 3-gram nasal tube, the instructions assume 3 grams total across 10 applications — about 0.3 grams per application.

Reconciling the thresholds: the standard course is twice daily × 5 days = 10 applications, the nasal-specific tube supplies approximately 3 grams for those 10 applications, and the regular 22-gram ointment tube is roughly 7 times larger and will not be consumed by a single nasal course. Do not extend the course past 5 days simply because ointment remains in the tube.

Side Effects and the Resistance Question, One Level Deeper

Local reactions are the usual complaint. Burning, stinging, itching, and redness in the nasal lining happen in a small percentage of users, typically under 5 percent in trials of the nasal formulation. These usually resolve without stopping the drug, but persistent discomfort is a reason to call the prescriber.

The less obvious risk is mupirocin resistance, which has been documented since the late 1980s. In settings with heavy, prolonged use, mupirocin-resistant S. aureus (often abbreviated as MuR) has emerged, sometimes at prevalence levels of 5 to 10 percent among hospital isolates in high-use centers. Once resistance is established, the nasal decolonization tool loses potency for everyone.

Self-treating with a skin tube for weeks or months raises that resistance risk substantially more than a single supervised 5-day course. Short, targeted courses preserve efficacy; long, unsupervised courses erode it.

In plain terms: a supervised 5-day course is a surgical strike; a self-directed multiweek course is a slow selection experiment.

Common Misconceptions and Edge Cases

One misconception is that all "regular mupirocin" is interchangeable with the nasal product. The active drug is the same, but the labeled site, the base, and the licensed indication are not. Using an internally labeled "not for ophthalmic or nasal use" product off-label should be a clinical decision, not a household habit.

Another misconception is that mupirocin prevents all staph infections. It reduces the risk in carriers, but it does not sterilize the whole person. The gut, throat, and skin remain possible reservoirs, and household contacts can reintroduce the bacterium.

Edge cases matter. People with a known polyethylene glycol hypersensitivity should not use the ointment base. Individuals with nasal mucosal injury, recent nasal surgery, or chronic nasal conditions like frequent epistaxis may be advised to avoid nasal ointment. Children need clinician-supervised dosing; pediatric nasal decolonization is used but the evidence base is thinner than in adults. Pregnant and breastfeeding people should consult a prescriber; systemic absorption from nasal mupirocin is very low, but the decision still belongs to the clinician.

What to Actually Do If You Think You Need It

Red flags that mean stop and call a clinician:

• Visible lesion, abscess, or fever with nasal symptoms
• Severe or worsening stinging, bleeding, or nasal discharge
• Known MRSA infection that is not responding
• Recurrent staph infections despite a prior course
• Any signs of systemic reaction such as rash, swelling, or difficulty breathing
• You are considering a second course within 3 months without a new swab

Positive steps:

• Confirm with your pharmacist that the exact tube is intended for the nose, not the skin.
• Use the prescribed frequency — usually twice daily — for the full 5 days unless told otherwise.
• Apply a small amount to each nostril and press the nostrils together to spread it.
• Wash your hands before and after each application.
• Avoid other nasal sprays or ointments during the course unless your clinician says otherwise.
• Return for a follow-up nasal swab if your care plan includes one.

Limits of the Evidence and When Not to Self-Treat

The strongest evidence for nasal mupirocin is in healthcare decolonization bundles and surgical-site prevention, not in self-managed nose complaints. There is no good evidence that regular mupirocin ointment helps with allergic rhinitis, sinus infection, dryness, or routine nasal irritation.

Absorption through the nasal lining is minimal, and the drug is cleared rapidly, which is why short courses are used rather than continuous therapy. That also means a single missed dose is not catastrophic, but chronic under-dosing is a quiet way to encourage resistance.

If you have a nasal symptom that is not clearly a staph colonization issue, the right move is a clinical evaluation, not an ointment experiment. If you do have a documented need for nasal decolonization, the prescribed course — five days, twice daily — is short, specific, and far safer than an open-ended habit.